COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Aggrenox To Treat Acute Covid-19 (ATTAC-19)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04410328
Recruitment Status : Not yet recruiting
First Posted : June 1, 2020
Last Update Posted : July 7, 2020
Boehringer Ingelheim
Information provided by (Responsible Party):
Amit Singla, MD, FAANS, Rutgers, The State University of New Jersey

No Study Results Posted on for this Study
Recruitment Status : Not yet recruiting
Estimated Primary Completion Date : December 15, 2020
Estimated Study Completion Date : December 15, 2021
Publications of Results:
Li Z LX, Huang Yi-Y et al. FEP-based screening prompts drug repositioning against COVID-19. 2020.
Liu X LZ, Liu S et al. . Therapeutic effects of dipyridamole on COVID-19 patients with coagulation dysfunction. 2020.

Other Publications:
International Severe Acute Respiratory emergning Infection Consortium Case Reports.